Chinese luxury electric vehicle maker Xpeng stock (NYSE:XPEV) posted a better-than-expected set of Q1 2024 results. Net losses came in narrower than expected at about $0.10 per share, while revenue grew by 62% to RMB 6.55 billion (about $910 million) driven by an expanding
The stock price of Sunrun stock (NASDAQ: RUN), a home solar panel and battery storage company, has surged over 25% in a month. This can be attributed to a broader rise in solar stocks, especially the ones that may benefit from increased energy demand for AI data centers. However,
Deutsche Bank’s stock (NYSE: DB) has gained 24% YTD, as compared to a 12% rise in the S&P500 over the same period. Further, it is currently trading at $17 per share, which is 17% above its fair value of just below $14 – Trefis’
Given its better prospects, we believe Verisign stock (NASDAQ: VRSN), a domain name provider, is a better pick than its industry peer, F5 Networks stock (NASDAQ: FFIV), an application security and cloud networking company. Investors have assigned a higher valuation multiple of 11
Nvidia (NASDAQ: NVDA) posted a better-than-expected set of Q1 FY’25 results on Tuesday, amid a growing uptake for the company’s high-end GPUs for artificial intelligence applications. Revenues for Q1 more than tripled year-over-year to about $26 billion, while net pro
Booz Allen Hamilton Holding Corp.’s (BAH) shares surged 4% after the company reported fourth-quarter fiscal 2024 adjusted earnings per share of $1.33, surpassing the Zacks Consensus Estimate of $1.22.Shares of Workday Inc. (WDAY)
Salesforce Inc. is set to release its earnings on Wednesday after the market close. The company recently started paying dividends and gave higher cash flow guidance. As a result, CRM stock looks cheap here.
Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. However, it isn't easy to find a great growth stock.
Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. However, it isn't easy to find a great growth stock.
Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. However, it isn't easy to find a great growth stock.
Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. But finding a great growth stock is not easy at all.
Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. However, it isn't easy to find a great growth stock.
Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a great growth stock is not easy at all.
Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a great growth stock is not easy at all.
Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. But finding a great growth stock is not easy at all.
Apellis Pharmaceuticals APLS, in collaboration with Sobi, reported positive one-year results from the mid-stage study evaluating systemic pegcetacoplan to treat post-transplant recurrence of C3 glomerulopathy (C3G) and primar
Zacks
Checked
18 minutes 37 seconds ago
This feed is responsible for generating the rss feed related to the topic Stocks